ArticleThe FEBS journal2026
Detection of endogenous LINE-1 ORF2p and its potent reverse transcriptase activity in the MCF-7 breast cancer cell line.
Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Long interspersed element-1 (LINE-1 or L1) is actively jumping in humans, notably in germ cells, neurons, and certain types of cancer. An active L1 is ~6.0 kb in length and encodes two proteins, designated ORF1p and ORF2p. L1 RNA binds with L1-encoded proteins and forms L1-ribonucleoprotein particles (L1-RNPs), the retrotransposition intermediate. Although cells that support L1 retrotransposition express both proteins, the detection of ORF2 protein (ORF2p) is extremely challenging due to its limited expression and unavailability of a suitable antibody. Here, we characterize an anti-ORF2p antibody and show the presence of endogenous L1-ORF2p in multiple cancer cell lines, among which the MCF-7 cell line showed notably high expression. Complexes purified by immunoprecipitation (IP) with anti-ORF2p or anti-ORF1p from MCF-7 or HEK293T cells contain ORF2p and ORF1p and show ORF2p-mediated reverse transcriptase (RT) activity on L1, Alu, and GAPDH RNA templates. The ORF2 IP complex was further purified by size exclusion chromatography (SEC), which showed three major peaks with molecular weights around 796, 427, and 239 kDa. All three peaks showed the presence of L1 proteins, RNA, and ORF2p-mediated RT activity. Although many proteins have been identified that interact with L1 proteins, it is unclear which of these belong to the core L1 RNP. Our novel anti-ORF2p will provide a valuable resource for future studies involving ORF2p IP followed by SEC to identify the protein components of core L1 RNPs. In summary, we report the detection of endogenous L1 ORF2 protein and partial purification of its complex by ORF2p antibody-coupled IP and SEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.